Sarcoma
Memorial Sloan Kettering names head of pediatric solid tumor division
Damon Reed, MD, has been appointed inaugural head of the division of pediatric solid tumors at Memorial Sloan Kettering Cancer Center.
AYA cancer survivors treated with cardiotoxic therapies exhibit accelerated cardiac aging
Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.
Incidence of HIV-related Kaposi’s sarcoma not improving in East Africa
SEATTLE — People in East Africa with HIV-related Kaposi’s sarcoma often have advanced disease and a poor survival outlook — and the situation has not improved in the last 5 years, a study found.
High incidence of secondary malignant neoplasms observed among young sarcoma survivors
Childhood, adolescent and young adult survivors of bone and soft tissue sarcomas had an increased risk for second malignant neoplasms, according to study results in Cancer.
FDA approves Tecentriq for unresectable or metastatic alveolar soft part sarcoma
The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic alveolar soft part sarcoma.
Childhood Cancer Awareness Month: Therapies exhibit efficacy for glioma, sarcoma, lymphoma
September is Childhood Cancer Awareness Month.
Program increases clinician-patient communication, shifts focus to ‘what matters most’
Despite recommendations in clinical guidelines, a high proportion of patients with advanced cancer do not have appropriate conversations with health care providers about prognosis, treatment options and end-of-life preferences.
Ifosfamide more likely to extend survival than topotecan-cyclophosphamide in Ewing sarcoma
CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide.
T-cell receptor therapy safe, effective for soft tissue sarcoma
CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft tissue sarcoma, according to results from a phase 1 study presented at ASCO Annual Meeting.
T-cell therapy shows antitumor activity for advanced myxoid/round cell liposarcoma
CHICAGO — A single infusion of letetresgene autoleucel demonstrated antitumor activity among patients with advanced or metastatic myxoid/round cell liposarcoma, results from a pilot study suggested.